Log in to search using one of your social media accounts:

 

Researchers Aiming To Suppress Therapy Resistance In Brain Cancer

Gliomas are malignant brain tumors that arise from glial cells called astrocytes, found in the central nervous system. "In treating malignant gliomas, we currently combine radiotherapy with the anticancer drug temozolomide. However, in some patients, tumors rapidly become resistant to both treatment methods," says neurooncologist Professor Dr. Michael Platten, who leads a cooperation unit of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the Department of Neurooncology of Heidelberg University Hospital...
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Related Links:

Publication date: Available online 13 December 2017 Source:Molecular Aspects of Medicine Author(s): Claudia Quezada, Ángelo Torres, Ignacio Niechi, Daniel Uribe, Susana Contreras-Duarte, Fernando Toledo, Rody San Martín, Jaime Gutiérrez, Luis Sobrevia The role of extracellular vesicles in cancer biology has emerged as a focus of the study of great importance and has been shown to directly influence tumour development in several cancers including brain tumours, such as gliomas. Gliomas are the most aggressive brain tumours, and in the last time, a considerable effort has been made to understand their b...
Source: Molecular Aspects of Medicine - Category: Molecular Biology Source Type: research
Publication date: Available online 21 November 2017 Source:Seminars in Cancer Biology Author(s): Olga Gusyatiner, Monika E. Hegi Gliomas are the most common malignant primary brain tumors, of which glioblastoma is the most malignant form (WHO grade IV), and notorious for treatment resistance. Over the last decade mutations in epigenetic regulator genes have been identified as key drivers of subtypes of gliomas with distinct clinical features. Most characteristic are mutations in IDH1 or IDH2 in lower grade gliomas, and histone 3 mutations in pediatric high grade gliomas that are also associated with characteristic DNA met...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Conclusion.Comprehensive genomic profiling of pediatric gliomas provides objective data that promote diagnostic accuracy and enhance clinical decision‐making. Additionally, TMB could be a biomarker to identify pediatric glioblastoma (GBM) patients who may benefit from immunotherapy.Implications for Practice.By providing objective data to support diagnostic, prognostic, and therapeutic decision‐making, comprehensive genomic profiling is necessary for advancing care for pediatric neuro‐oncology patients. This article presents the largest cohort of pediatric low‐ and high‐grade gliomas profiled by next‐generation ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Neuro-Oncology, Precision Medicine ‐ Source Type: research
Conclusion: Our study suggests that WWP2 may play a role in the genesis and development of glioma; it may be a potential biomarker to predict pathological grade and tumor recurrence in patients with glioma.
Source: Journal of Cancer Research and Therapeutics - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: The results of this study propose a healthy diet such as high intake of vitamins C and E, calcium, fiber, food groups like fruits and vegetables, and low-fat milk and nuts; and low consumption of total fat, SFA, and red meat may be protective against glioma. PMID: 29236551 [PubMed - as supplied by publisher]
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Tags: Nutr Cancer Source Type: research
In this experimental and computational study, three biophysical models are developed and evaluated for their ability to accurately describe in vivo growth and response following whole brain radiotherapy. Models that include reduced proliferation post-radiotherapy more accurately predicted future tumor growth.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Biology Contribution Source Type: research
NCI's Center for Cancer Research (CCR) Grand Rounds As a physician – scientist, Dr. Okada has been dedicated to brain tumor immunology and development of effective immunotherapy for brain tumor patients for over 20 years. His team was one of very first to discover cytotoxic T lymphocyte (CTL) epitopes in glioma-associated and glioma-specific antigens. Dr. Okada also found critical roles for the integrin receptor very late activation antigen (VLA)-4 and the chemokine CXCL10 in facilitating entry of CTLs to the brain tumor site. Dr. Okada has translated these discoveries into a number of innovative immunotherapy clinic...
Source: Videocast - All Events - Category: General Medicine Tags: Upcoming Events Source Type: video
Authors: Wang HH, Liao CC, Chow NH, Huang LL, Chuang JI, Wei KC, Shin JW Abstract Glioblastoma multiforme (GBM) is one of the most malignant and aggressive brain tumors with great amount of hyaluronan (HA) secretion and CD44 overexpression (HA receptor). CD44 has been suggested as a cancer stem cells (CSCs) marker. However, several clinical studies have indicated that CD44low glioma cell exhibit CSCs traits. Additionally, our previous study indicated that more CD44 expression was associated with a better prognosis in GBM patients. To determine whether CD44 is an appropriate marker of glioma stem cells (GSCs), we ma...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Glioma remains the most common cause of brain cancer-related mortality. Glioma accounts for 50 –60% of brain cancer. Due to their low toxicity and infrequent side effects, traditional herbs have been increasing...
Source: BMC Complementary and Alternative Medicine - Category: Complementary Medicine Authors: Tags: Research article Source Type: research
AbstractGliomas are primary malignancies of the brain. Tumors are staged based on malignancy, nuclear atypia, and infiltration of the surrounding brain parenchyma. Tumors are often diagnosed once patients become symptomatic, at which time the lesion is sizable. Glioblastoma (grade IV glioma) is highly aggressive and difficult to treat. Most tumors are diagnosed de novo. The gold standard of therapy, implemented over a decade ago, consists of fractionated radiotherapy and temozolomide, but unfortunately, chemotherapeutic resistance arises. Recurrence is common after initial therapy. The tumor microenvironment plays a large ...
Source: Journal of Neurology - Category: Neurology Source Type: research
More News: Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Glioma | Health | Hospitals | Neurology | Temodar